| scholarly article | Q13442814 |
| P50 | author | Stefania Chiappini | Q88459395 |
| Amira Guirguis | Q89410322 | ||
| John Corkery | Q55128379 | ||
| P2093 | author name string | Fabrizio Schifano | |
| P2860 | cites work | Clozapine: a review of clinical practice guidelines and prescribing trends | Q21260307 |
| Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia | Q24240093 | ||
| Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel | Q28243410 | ||
| Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex | Q28264575 | ||
| Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy | Q28291415 | ||
| Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data. | Q30765869 | ||
| Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine | Q32052895 | ||
| Significant interaction between clozapine and cocaine in cocaine addicts | Q33145592 | ||
| Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey | Q33827207 | ||
| Clozapine withdrawal. A review | Q33899863 | ||
| Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | Q33996824 | ||
| Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review | Q34043285 | ||
| Evidence that clozapine directly interacts on the GABAB receptor. | Q34200230 | ||
| Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review | Q90408654 | ||
| Review of withdrawal catatonia: what does this reveal about clozapine? | Q90672919 | ||
| The clinical challenges of synthetic cathinones | Q91052529 | ||
| The art of clozapine therapy and "clozaphobia" | Q91360505 | ||
| Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis | Q92944239 | ||
| Clozapine-withdrawal catatonia | Q95806221 | ||
| Clinical implications of clozapine discontinuation: report of an NIMH workshop. | Q52021048 | ||
| Misuse of Trihexyphenidyl (Artane) on Réunion Island. | Q52317331 | ||
| Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. | Q52318376 | ||
| Is There a Potential of Misuse for Venlafaxine and Bupropion? | Q52606203 | ||
| Catatonia following abrupt stoppage of clozapine. | Q53964235 | ||
| Antidepressant discontinuation syndrome | Q56700905 | ||
| Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports | Q57031331 | ||
| Effect of chronic treatment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain | Q59328597 | ||
| Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems | Q61803804 | ||
| Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis | Q62079448 | ||
| Acute Clozapine Overdose: Plasma Concentration and Outcome | Q63258569 | ||
| Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics | Q64077265 | ||
| A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder | Q64260521 | ||
| An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions | Q64286278 | ||
| An overview of the mechanism of action of clozapine | Q72808224 | ||
| Acute clozapine overdosage | Q73523098 | ||
| Recurrent clozapine and lorazepam withdrawal psychosis with catatonia | Q83865702 | ||
| Managing clozapine discontinuation - acute and chronic maintenance strategies | Q85300920 | ||
| Sudden-Onset Catatonia Following Clozapine Withdrawal: A Case Report | Q88010840 | ||
| Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine | Q88277546 | ||
| The nature of the discontinuation syndrome associated with antidepressant drugs | Q34523366 | ||
| Neuroleptic Blockade of the Effect of Various Neurotransmitter Substances | Q34662872 | ||
| Managing suicide risk in patients with schizophrenia | Q34664040 | ||
| Novel psychoactive substances of interest for psychiatry. | Q34667835 | ||
| Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior? | Q34681144 | ||
| Serotonin syndrome associated with clozapine withdrawal. | Q34764901 | ||
| Agonist activity of N-desmethylclozapine at delta-opioid receptors of human frontal cortex | Q34951242 | ||
| Fatalities associated with therapeutic use and overdose of atypical antipsychotics | Q35094625 | ||
| The delta opioid receptor: an evolving target for the treatment of brain disorders | Q35400738 | ||
| Clinical pharmacology of atypical antipsychotics: an update. | Q35728228 | ||
| Hemoperfusion in the treatment of acute clozapine intoxication in China | Q37001271 | ||
| Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders | Q37075982 | ||
| Delta opioid receptors in brain function and diseases | Q37179419 | ||
| Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics. | Q37638936 | ||
| Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review | Q37726344 | ||
| Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study | Q38646571 | ||
| Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. | Q38653214 | ||
| The link between schizophrenia and substance use disorder: A unifying hypothesis | Q38729376 | ||
| Geographical disparities in prescription practices of lithium and clozapine: a community-based study | Q40041318 | ||
| Clozapine withdrawal emergent dystonia, oculogyric crisis and rebound psychosis in a single patient | Q40390149 | ||
| alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs | Q40670096 | ||
| Clozapine cases with fatal, toxic or therapeutic concentrations | Q40719581 | ||
| Clozapine as a drug of dependence | Q40814842 | ||
| Effects of clozapine on the delta- and kappa-opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes | Q42452233 | ||
| Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. | Q42944800 | ||
| Clozapine-withdrawal catatonia | Q43001726 | ||
| Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). | Q44268852 | ||
| Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex | Q44808036 | ||
| Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report | Q45189024 | ||
| Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. | Q46581750 | ||
| Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal | Q46872086 | ||
| Clozapine withdrawal syndrome | Q47172884 | ||
| Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database | Q47359368 | ||
| Geographical and temporal variations in clozapine prescription for schizophrenia. | Q47905209 | ||
| Unique Effects of Clozapine: A Pharmacological Perspective | Q50138280 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P577 | publication date | 2020-02-16 | |
| P1433 | published in | Brain Sciences | Q27724596 |
| P1476 | title | Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database | |
| P478 | volume | 10 |
| Q96773916 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia |
| Q94586898 | [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic] |
Search more.